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expand the potential clinical applications 
of this vector. Most importantly, this 
work convincingly demonstrates that 
ectopic expression of a single miRNA 
can markedly impact a disease, in this 
case hepatic cancer. AAV vectors can 
be produced in large quantities making it 
highly suitable as a gene therapy vector. 
Given that AAV vectors do not integrate 
into the host genome, they will eventu-
ally be eliminated, thereby minimizing 
the potential of vector-mediated tox-
icities. What is truly exciting about this 
study is the strong correlation between 
miR-26a expression and suppression of 
hepatic cancer. Restoring miR-26a levels 
in hepatic cancer cells via transduction 
with AAV vectors is clearly a path to the 
clinic that will be exploited given the high 
prevalence of liver cancer worldwide. 
The use of a natural miRNA to suppress 
cell proliferation is exciting and hopefully 
will lead to a new therapeutic strategy for 
the treatment of liver cancer.
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Why are some cell types more prone to transformation than others? In this issue, Xu et al. (2009) 
show that retinoblastoma cells co-opt several intrinsic features of cone photoreceptors for their 
survival and growth.Successful thieves select targets care-
fully, knowing that a well-guarded estab-
lishment is unlikely to surrender the loot. 
Oncogenic insults are like thieves in this 
regard, as their effect is highly dependent 
on cell type. Their mission is more likely to 
succeed in a cell where the defenses, such 
as death, terminal differentiation, senes-
cence, or sensitivity to immune surveil-
lance, are weaker. The last few decades 
have exposed most of the culprits, a 
scurrilous cast of activated oncogenes 
and inactivated tumor suppressors, but 
the cell-specific weaknesses—the inside 
crew—that allow them to flourish are more 
mysterious.
Now, David Cobrinik and colleagues 
redress this balance for the childhood 
ocular cancer, retinoblastoma (Xu et al., 
2009). This tumor is initiated by inactiva-
tion of both copies of retinoblastoma 1 992 Cell 137, June 12, 2009 ©2009 Elsevier(RB1) and helped along by subsequent 
genetic events (Figure 1A) (Corson and 
Gallie, 2007). Xu et al. now expose a quar-
tet of insiders that help these oncogenic 
events to take hold: N-Myc, MDM2, and 
the nuclear receptors RXRγ and THRβ2 
(Figure 1B). Although their presence is 
essential for tumorigenesis, they are 
not altered by any genetic, epigenetic, 
or posttranscriptional events typically 
associated with oncogene activation.
To expose retinoblastoma’s col-
laborators, the authors first defined the 
predominant cell type in retinoblas-
toma. Prior studies generated conflict-
ing conclusions, failing to distinguish 
normal versus tumor cells. This issue is 
elegantly resolved by Xu et al., who in 
one approach follow RB protein to mark 
normal cells, and in an even better strat-
egy select tumors with a homozygous  Inc.RB1 deletion and used fluorescent in situ 
hybridization to distinguish null tumor 
from normal cells. Colabeling reveals 
that most RB1-deficient tumor cells 
resemble cone photoreceptors, the cells 
that allow us to see color. Markers pres-
ent include the retinoic acid-activated 
nuclear receptor RXRγ and the home-
odomain protein CRX (which are also 
expressed in some other retinal neu-
rons) as well as the cone-specific thy-
roid hormone-activated nuclear recep-
tor, THRβ2, and two opsins. Humans 
have three types of cones with distinct 
opsins that detect blue (short wave, S), 
green (medium wave, M), and red (long 
wave, L) light. Xu et al. show that retino-
blastoma is replete with markers of M/L 
cones. This fits well with the presence of 
THRβ2, which blocks S and promotes 
L/M cones (Ng et al., 2001).
figure 1. Retinoblastoma’s Accomplices
(A) RB1 loss initiates ectopic division (blue nuclei). Tumor progression is driven by the subsequent changes indicated. Normal aspects of cone circuitry 
cooperate with these alterations. Tumors might exploit these features of cone precursors (Route 1), but may reroute to a cone fate after initially exploiting 
features of another cell type (Route 2).
(B) E2F1 sparks ectopic division of differentiating cells and can also activate p53 through various pathways, including induction of ARF. Intrinsically high 
levels of MDM2 counter that effect, promoting survival. High levels of N-Myc, perhaps important in normal cones to drive ribosome synthesis, are co-
opted along with E2F to drive division in retinoblastoma. The nuclear receptors RXRγ and THRβ2 (which may interact) are involved in cone development. 
THRβ2 inhibits synthesis of S cones, which respond to short wavelength light, promoting differentiation of cones that respond to medium and long wave-
lengths. RXRγ and THRβ2 are also required for survival and possibly division and other tumorigenic functions in retinoblastoma. Red, antitumorigenic 
factors; blue, protumorigenic factors/events; black, neutral factors.
(C) Imaging of the retina of an RB1+/− child a few weeks after birth by live Bioptigen fourier domain optical coherence tomography (kindly provided by 
A. Mallipatna, C. Vandenhoven, B.L. Gallie, and E. Héon). The retinal pigment epithelium lines the back of the eye. Photoreceptors (cones and rods) in 
the outer nuclear layer (ONL) form synapses in the outer plexiform layer (OPL) with interneurons in the inner nuclear layer (INL). These cells then form 
synapses in the inner plexiform layer (IPL) with neurons in the ganglion cell layer (GCL). Finally, ganglion cells generate a nerve fiber layer (NFL) that con-
nects to the brain. The nascent tumor is emerging in the INL, rather than the ONL.In mice, Rb1 loss causes abnormal divi-
sion of differentiating retinal cells (Chen 
et al., 2004; MacPherson et al., 2004). 
If we assume that the fetal human retina 
responds similarly to RB1 deficiency, a 
critical question emerges: what advan-
tages does the L/M cone circuitry offer a 
tumor that other retinal cells do not?
The first suspect nabbed is the infa-
mous MDM2, which can counter E2F1-
induced death. Given that the absence 
of RB triggers E2F1-dependent division 
in differentiating retinal neurons and con-
comitant apoptosis in a subset (Chen et 
al., 2007), MDM2 could be useful for an 
aspiring retinoblastoma cell. MDM2 is 
often amplified in human tumors with 
wild-type p53, but copy number is unaf-
fected in retinoblastoma. Others report 
amplification of the MDM2-relative MDM4 
in retinoblastoma (Laurie et al., 2006), but 
Xu et al. report two copies in most of their 
samples. Strikingly, in normal develop-
ment, fetal human cones the levels of 
MDM2 are intrinsically high. This finding 
invokes an attractive model in which high levels of MDM2 in retinoblastoma reflects 
cone identity rather than oncogenic mis-
chief.
Xu et al. reveal that cones and retino-
blastoma also share high levels of N-Myc. 
Knockdown of MDM2 or N-Myc impairs 
division and increases apoptosis in retino-
blastoma cell lines. Reducing ARF levels 
limits the effect of MDM2 knockdown, sug-
gesting that MDM2 acts via the ARF-p53 
pathway (Figure 1B), confirming the rel-
evance of p53 inactivation to retinoblas-
toma (Laurie et al., 2006). MDM2 expres-
sion in retinoblastoma requires recruitment 
of the nuclear receptor RXRγ to the MDM2 
promoter, and strikingly, RXRγ knockdown 
reduces MDM2 expression and retino-
blastoma cell survival.
Of the four factors revealed by Xu et 
al., THRβ2 is the only one whose func-
tion is probed in an orthotopic xenograft 
assay, which shows that tumor growth is 
reduced in the absence of THRβ2. Both 
thyroid and retinoic acid receptors are 
important for cone development, and the 
MDM2-inducing function of RXRγ helps Cell explain its tumorigenic value, but how is 
THRβ2 involved? Thyroid hormone has 
a long-standing but complex association 
with cancer. THRα is the cellular version 
of the v-ErbA oncogene, but v-ErbA and 
altered versions of THRβ found in human 
cancer are dominant negatives, suggest-
ing a tumor suppressor function for unal-
tered THRβ (Guigon and Cheng, 2009). 
Given that THRs can affect division, differ-
entiation, and migration, and interact with 
RXR and various oncoproteins and tumor 
suppressors (such as β-catenin, a PI3K 
regulator, Cyclin D1, RB, and p53), THRβ2 
could promote retinoblastoma in diverse 
ways.
The value of N-Myc/MDM2 to retino-
blastoma is obvious, but why do post-
mitotic cones retain these proteins? The 
role of MDM2 in survival could be useful 
in these long-lived neurons. Myc proteins 
target thousands of genes regulating 
many processes, including ribosome bio-
genesis, and cones need millions of opsin 
molecules to feed their hungry outer 
segments. One wonders how N-Myc-137, June 12, 2009 ©2009 Elsevier Inc. 993
deficient rods cope, which are larger in 
size than cones and need 100,000,000 
opsins/cell.
The unaltered insiders discussed above 
are altered in other cancers; thus, whether 
abnormal or normal activity of a particular 
gene contributes to tumorigenesis is con-
text dependent. There must also be genes 
that are expressed in one cell, where they 
counter transformation, and are naturally 
off in a neighbor, increasing its suscep-
tibility. Discovering the basal unaltered 
features of different cell types that render 
them more cancer prone will expand the 
repertoire of potential therapies. Several 
labs are already testing MDM2/4 thera-
peutics, and if thyroid hormone is required 
for cancer-promoting activity of THRβ2, 
perturbations in its transport or activation 
may also be helpful.
The cone phenotype of retinoblastoma 
suggests, but does not prove, that the dis-
ease originates from cones. Passengers 
disembarking from a plane wearing winter 
coats imply a chilly origin, but equally could 
signify a frigid destination. Guessing where 
cancer starts from its end-stage appear-
ance is equally ambiguous. If retinoblas-
toma arises from cones, one would expect 
more tumors at the fovea, a cone-rich 
region located within the posterior (cen-
tral) human retina. When newborn children 
with heterozygous loss of RB1 are tracked, 
nascent tumors do appear first at the poste-994 Cell 137, June 12, 2009 ©2009 Elsevier
Transmissible spongiform encephalopa-
thies, or prion diseases, are neurode-
generative conditions caused by prions, 
atypical infectious agents consisting of 
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Inactivation of mahogunin, an E3
prion disease. Chakrabarti and H
inactivate mahogunin, providing rior pole, but not preferentially at the fovea, 
and tumors also arise later in the periphery 
(B. Gallie, personal communication), which 
fits the posterior-anterior developmental 
wave rather than a cone origin. Cones in 
the outer retina synapse with interneurons 
in the inner nuclear layer. Tumors have been 
observed emerging here (Figure 1C), which 
may arise from displaced cones, or vari-
ous interneurons or Müller glia in the inner 
nuclear layer. Retinoblastoma in mice also 
arises in the inner nuclear layer, exploiting 
the intrinsically high resistance of amacrine 
or horizontal neurons to apoptosis (Ajioka 
et al., 2007; Chen et al., 2004; MacPherson 
et al., 2004). Emerging from one ground 
state and converting to another seems 
elaborate, but altering cell type is not oner-
ous (induced pluripotent stem cells are a 
topical example), and “transformation” is 
cancer’s defining feature. Until the early 
response of different human retinal cells 
to RB1 loss and the routes adopted dur-
ing progression are understood, we remain 
(cones or no cones) very much in the dark. 
Wherever it is first employed, the cone 
circuitry is clearly a crucial component in 
retinoblastoma.
Like other breakthroughs in the study of 
retinoblastoma, the latest milestone has 
significance well beyond the eye. Normal 
is not the same as harmless. As genome-
wide sequencing projects continue 
onward toward the goal of uncovering all  Inc.
PrPSc, a misfolded and aggregated form 
of the cellular prion protein (PrPC). PrPC 
is a cell-surface GPI-anchored glycopro-
tein that is normally produced in abun-
 and toxicity
2,*
tal Zurich, Zurich CH-8091, Switzerland
nology, Pasadena, CA 91125, USA
.), steelea@caltech.edu (A.D.S.)
 ubiquitin ligase, causes a spongifo
egde (2009) now report that prion p
a plausible explanation for certain oncogenic mutations in all tumor types, 
the next major step will be to expose their 
hidden accomplices.
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